<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04982146</url>
  </required_header>
  <id_info>
    <org_study_id>BROAC-PMP</org_study_id>
    <nct_id>NCT04982146</nct_id>
  </id_info>
  <brief_title>Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei</brief_title>
  <official_title>Intratumoral Bromelain + N-acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei. Phase I Single-arm Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimónides Biomedical Research Institute of Córdoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimónides Biomedical Research Institute of Córdoba</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial pursues studying a compassionate treatment option for patients with inoperable&#xD;
      pseudomyxoma peritonei through percutaneous administration of bromelain + N-acetylcysteine&#xD;
      (NAC) in order to decrease tumoral volume. Secondary endpoints are the decrease of ascites,&#xD;
      compressive symptoms and pain through the dilution of mucins, which would better intestinal&#xD;
      blockage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single-arm experimental analytical study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumoral Mass Change</measure>
    <time_frame>Day 3, Day 7 (if it applies),1 month and 12 months after treatment is finished.</time_frame>
    <description>Tumoral mass change calculated through CT Scan or Magnetic Resonance categorized regarding the biggest diameter per abdominal region</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms improvement</measure>
    <time_frame>Basal visit, 1 month and 12 months after treatment.</time_frame>
    <description>Symptoms progression evaluated through QLQ-C30 questionnaire (life quality questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTP (Time to tumor progression)</measure>
    <time_frame>Period of 12 months after treatment.</time_frame>
    <description>Period of time free of tumor progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Period of 12 months after treatment.</time_frame>
    <description>Time until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumoral DNA diminution in biological samples</measure>
    <time_frame>Basal visit, all treatment visits and 12 months after treatment is finished.</time_frame>
    <description>Diminution of tumoral DNA amount found in mucin and blood samples</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pseudomyxoma Peritonei</condition>
  <arm_group>
    <arm_group_label>Bromelain + N-Acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with pseudomyxoma peritonei that are not candidates to surgical resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromelin</intervention_name>
    <description>0.5mg per mL of total tumor volume calculated, administered percutaneously</description>
    <arm_group_label>Bromelain + N-Acetylcysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Acetylcysteine</intervention_name>
    <description>20mg per mL of total tumor volume calculated, administered percutaneously</description>
    <arm_group_label>Bromelain + N-Acetylcysteine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pseudomyxoma peritonei diagnosis through imaging tests and/or histological studies&#xD;
&#xD;
          -  Pseudomyxoma peritonei relapse in abdominal area in patients who comply inoperability&#xD;
             criteria, which are:&#xD;
&#xD;
        At least two HIPEC operations or major abdominal surgery (PSS &gt; 3). Patients with acute&#xD;
        morbidities (ASA score IV)&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  Signs informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Candidates to other potentially healing treatments&#xD;
&#xD;
          -  Allergy to bromelains (pineapple), N-Acetylcysteine or possible cross-reactive allergy&#xD;
             (eggs, sulphate. latex, carrots, celery, wheat...)&#xD;
&#xD;
          -  Non-manageable coagulation alterations&#xD;
&#xD;
          -  No possibility of intraabdominal drainage catheter&#xD;
&#xD;
          -  Acute respiratory pathology (asthma, COPD), acute hepatic, cardiopathic or kidney&#xD;
             pathology&#xD;
&#xD;
          -  Allergy to any substance that might cause crossed reactivity to bromelain&#xD;
&#xD;
          -  Unwillingness to participate in this clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lidia Rodríguez Ortiz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Reina Sofía</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Álvaro Arjona Sánchez, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Reina Sofía</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Álvaro Arjona Sánchez, PhD</last_name>
    <phone>0034600328402</phone>
    <email>alvaroarjona@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antonio Luque</last_name>
    <phone>+34 671 596 070</phone>
    <email>uicec@imibic.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Álvaro Arjona Sánchez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alvaro Arjona, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lidia Rodríguez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pseudomyxoma peritonei</keyword>
  <keyword>n-acetylcysteine</keyword>
  <keyword>acetylcysteine</keyword>
  <keyword>NAC</keyword>
  <keyword>bromelain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudomyxoma Peritonei</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared after the study concludes and results are published</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After results publication</ipd_time_frame>
    <ipd_access_criteria>Upon request to study's principal investigator</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

